Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
2006-03-21
2006-03-21
Jones, Dwayne (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
C514S557000
Reexamination Certificate
active
07015250
ABSTRACT:
A method whereby the blood pressure metabolism in an individual showing evidence of dysregulation is improved when that person receives an appropriate oral administration of (−)-hydroxycitric acid. The potassium salt of (−)-hydroxycitric acid is a preferred form of the compound, followed by the sodium salt, then by the amide and other derivatives of the acid. The regulation of blood pressure levels over any given period of time may be improved with a controlled release form of (−)-hydroxycitric acid. Controlled release can be used to provide a sustained and modulated amount of the active to the body as desired and therefore regulate the use of the compound as a hypotensive agent.
REFERENCES:
patent: 3764692 (1973-10-01), Lowenstein
patent: 3767678 (1973-10-01), Guthrie et al.
patent: 3919254 (1975-11-01), Guthrie et al.
patent: 3993668 (1976-11-01), Guthrie et al.
patent: 5626849 (1997-05-01), Hastings et al.
patent: 5656314 (1997-08-01), Moffett et al.
patent: 5783603 (1998-07-01), Majeed et al.
patent: 5914326 (1999-06-01), McCarty et al.
patent: 6221901 (2001-04-01), Shrivastava et al.
patent: 803202 (1997-10-01), None
patent: 0803202 (1997-10-01), None
DiPiro et al., Editor, Pharmacotherapy, A Pathophysiologic Approach, 1989, pp. 805-811.
Solomons, T. W. G., Organic Chemistry, 3rdEdition, 1984, pp. 799-800.
McMurry, J., Organic Chemistry, 2ndEdition, 1988, pp. 759-767.
Sullivan, A. C. et al., “Metabolic Regulation as a Control for Lipid Disorders. I. Influence of (-)-Hydroxycitrate on Experimentally Induced Obesity in the Rodent” The American Journal of Clinical Nutrition,30: May 1977, pp. 767-776.
Hardman, J.G. editor-in-chief, of Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9thEdition, p. 803-804, 1996.
DiPiro et al. Editor, Pharmacotherapy, A Pathophysiologic Approach, 1989, pp. 97-102 and 805-811, 1989.
Solomons, T. W. G., Organic Chemistry, 3rdEdition, 1984, pp. 799-800.
McMurry, J. Organic Chemistry, 2NDEdition, 1988, pp. 759-767.
Benson S, Vance-Bryan K, Raddatz J. Time to patient discontinuation of antihypertensive drugs in different classes. Am J Health Syst Pharm. Jan. 1, 2000 ;57(1):51-4.
Cusin I, Rohner-Jeanrenaud F, Terrettaz J, Jeanrenaud B. Hyperinsulinemia and its impact on obesity and insulin resistance. Int J Obes Relat Metab Disord. Dec. 1992;16 Suppl 4:S1-11.
Ishihara K, Oyaizu S, Onuki K, Lim K, Fushiki T. Chronic (-)-hydroxycitrate administration spares carbohydrate utilization and promotes lipid oxidation during exercise in mice. J Nutr. Dec. 2000;130(12):2990-5.
McCarty MF. Toward a wholly nutriontional therapy for type 2 diabetes. Med Hypotheses Mar. 2000;54(3):483-487.
McCarty MF. Promotion of hepatic lipid oxidation and gluconeogenesesis as a strategy for appetite control. Medical Hypotheses 1994;42:215-225.
Preuss HG, Burris JF. Adverse metabolic effects of antihypertensive drugs. Implications for treatment. Drug Saf. Jun. 1996;14(6):355-64.
Sowers JR, Bakris GL. Antihypertensive therapy and the risk of type 2 diabetes mellitus. N Engl J Med. Mar. 30, 2000;342(13):969-70.
Sullivan AC, Triscari J. Metabolic regulation as a control for lipid disorders. I. Influence of (-)-hydroxycitrrate on experimentally induced obesity in the rodent. American Journal of Clinical Nutrition 1977;30:767.
Sullivan, Ann C. and Joseph Triscari. Possible interrelationship between metabolite flux and appetite. In D. Novin, W. Wyriwicka and G. Bray, eds., Hunger: Basic Mechanisms and Clinical Implications (New York: Raven Press,1976) 115-125.
Clouatre Dallas L.
Dunn James M.
Ewing James F.
Foley & Lardner LLP
Glykon Technologies Group, LLC
Jones Dwayne
Morency Michel
LandOfFree
Methods and pharmaceutical preparations for normalizing... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and pharmaceutical preparations for normalizing..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and pharmaceutical preparations for normalizing... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3558882